Relmada Therapeutics, Inc. (RLMD)

7.265 +0.02 (+0.35%) USD  |  NASDAQ  |  Apr 29, 14:44
More

Relmada Therapeutics Revenue Estimates for Next Fiscal Year

Revenue Estimates for Next Fiscal Year Chart

View Revenue Estimates for Next Fiscal Year for RLMD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Next Fiscal Year Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Revenue Estimates for Next Fiscal Year Range, Past 5 Years

View Revenue Estimates for Next Fiscal Year Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Next Fiscal Year Benchmarks

View Revenue Estimates for Next Fiscal Year Benchmarks
Start Trial
Catalyst Pharmaceuticals, Inc. Upgrade
Theravance Biopharma, Inc. Upgrade
Avalo Therapeutics, Inc. Upgrade
AN2 Therapeutics, Inc. Upgrade
ACADIA Pharmaceuticals, Inc. Upgrade

Revenue Estimates for Next Fiscal Year Related Metrics

EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade